These polymorphisms may not alter the CTLA-4 amino-acid sequence but can affect the affinity for CTLA-4 mAbs, thereby increasing the risk of immunotherapy-induced autoimmune disorders [72]. The gene discussed is CTLA4; the disease is autoimmune disease.